Position in PGEN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,071,901
-$11,983,096 QoQ
Shares Held
793,773
-78.0% QoQ
Ownership
0.222%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 77%
Shared 0%
None 23%
Common Shares in PGEN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Driehaus Capital Management LLC holds $3,707,249,767 across 60 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
|
6,845,276 | $322,001,783 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
959,048 | $321,079,679 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
4,418,557 | $266,704,100 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
2,799,166 | $248,509,957 | |
| 5 | 6,463,551 | $241,866,078 | |||
| 6 | 1,740,101 | $230,963,605 | |||
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
4,728,623 | $192,123,952 | |
| 8 | SEPN |
Septerna, Inc.
|
4,433,058 | $148,463,112 |
All Filings in PGEN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,071,901 | 793,773 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $15,054,997 | 3,601,674 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $6,719,857 | 2,042,510 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||